Vaccine effectiveness of 52.8% seen for ED visits, 52.3% for noncritical hospitalization, 50.4% for critical hospitalization.

Antiretroviral therapy recommended for all individuals with HIV; recommendations provided for those with specific clinical circumstances ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.

The phase 3 STEER study enrolled 127 treatment-naïve patients aged 2 to less than 18 years with SMA type 2 who were able to sit but had never walked independently.

The ongoing shortage of liraglutide injection and other GLP-1 medications prompted the FDA to prioritize the generic drug applications for these medications in order to improve patient access.

Results from the VENTURE trial showed significant reductions in weight and hunger among younger patients treated with ...

The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.

Administration of therapeutic- versus prophylactic-dose anticoagulation with heparins linked to lower mortality in patients hospitalized for COVID-19 ...